Literature DB >> 15606766

Enhanced peptide secretion by gene disruption of CYM1, a novel protease in Saccharomyces cerevisiae.

Lars Jønson1, Jens F Rehfeld, Anders H Johnsen.   

Abstract

Saccharomyces cerevisiae is a widely used host in the production of therapeutic peptides and proteins. Here we report the identification of a novel endoprotease in S. cerevisiae. It is encoded by the CYM1 gene and is specific for the C-terminus of basic residues of heterologously expressed peptides. Gene disruption of CYM1 not only reduced the intracellular proteolysis, but also enhanced the secretion of heterologously expressed peptides such as growth hormone, pro-B-type natriuretic peptide and pro-cholecystokinin. Cym1p resembles metalloendoproteases of the pitrilysin family with the HXXEH(X)E(71-77) catalytic domain as seen in insulysin, nardilysin and human metalloprotease 1. It is a nuclear encoded protease that localizes to mitochondria without a hydrophobic N-terminal signal sequence or a C-terminal tail-anchor. The protease does not require post-translational processing prior to activation and it contains cytosolic activity that processes peptides designated for the secretory pathway prior to translocation into the endoplasmic reticulum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15606766     DOI: 10.1111/j.1432-1033.2004.04443.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

Review 1.  Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells.

Authors:  Aleš Berlec; Borut Strukelj
Journal:  J Ind Microbiol Biotechnol       Date:  2013-02-06       Impact factor: 3.346

2.  A yeast exosome cofactor, Mpp6, functions in RNA surveillance and in the degradation of noncoding RNA transcripts.

Authors:  Laura Milligan; Laurence Decourty; Cosmin Saveanu; Juri Rappsilber; Hugo Ceulemans; Alain Jacquier; David Tollervey
Journal:  Mol Cell Biol       Date:  2008-06-30       Impact factor: 4.272

3.  Functional requirement for human pitrilysin metallopeptidase 1 arginine 183, mutated in amyloidogenic neuropathy.

Authors:  Jillian E Smith-Carpenter; Benjamin J Alper
Journal:  Protein Sci       Date:  2018-02-23       Impact factor: 6.725

Review 4.  Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up.

Authors:  Aravind Madhavan; K B Arun; Raveendran Sindhu; Jayaram Krishnamoorthy; R Reshmy; Ranjna Sirohi; Arivalagan Pugazhendi; Mukesh Kumar Awasthi; George Szakacs; Parameswaran Binod
Journal:  Microb Cell Fact       Date:  2021-06-30       Impact factor: 5.328

5.  Assessment of inactivating stop codon mutations in forty Saccharomyces cerevisiae strains: implications for [PSI] prion- mediated phenotypes.

Authors:  David A Fitzpatrick; Jennifer O'Brien; Ciara Moran; Naushaba Hasin; Elaine Kenny; Paul Cormican; Amy Gates; Derek W Morris; Gary W Jones
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

6.  Quantitative differential proteomics of yeast extracellular matrix: there is more to it than meets the eye.

Authors:  Fábio Faria-Oliveira; Joana Carvalho; Célia Ferreira; Maria Luisa Hernáez; Concha Gil; Cândida Lucas
Journal:  BMC Microbiol       Date:  2015-11-25       Impact factor: 3.605

7.  Improved production of recombinant Rhizomucor miehei lipase by coexpressing protein folding chaperones in Pichia pastoris, which triggered ER stress.

Authors:  Jinjin Huang; Qingyi Zhao; Lingxiao Chen; Chunmei Zhang; Wei Bu; Xin Zhang; Kaini Zhang; Zhen Yang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.